<?xml version="1.0" encoding="UTF-8"?><xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:e="http://xbrl.dcca.dk/sob" xmlns:b="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature" xmlns:h="http://xbrl.dcca.dk/mrv" xmlns:f="http://xbrl.dcca.dk/arr" xmlns:d="http://xbrl.dcca.dk/cmn" xmlns:g="http://xbrl.dcca.dk/fsa" xmlns:c="http://xbrl.dcca.dk/gsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature http://archprod.service.eogs.dk/taxonomy/20201001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20201001.xsd"><link:schemaRef xlink:type="simple" xlink:href="http://archprod.service.eogs.dk/taxonomy/20201001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20201001.xsd"/><c:NameOfSubmittingEnterprise contextRef="c179" xml:lang="en">BDO Statsautoriseret revisionsaktieselskab</c:NameOfSubmittingEnterprise><c:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="c179" xml:lang="en">Fælledvej 1</c:AddressOfSubmittingEnterpriseStreetAndNumber><c:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="c179" xml:lang="en">DK-5000 Odense C</c:AddressOfSubmittingEnterprisePostcodeAndTown><c:IdentificationNumberCvrOfSubmittingEnterprise contextRef="c179" xml:lang="en">20222670</c:IdentificationNumberCvrOfSubmittingEnterprise><c:InformationOnTypeOfSubmittedReport contextRef="c179">Årsrapport</c:InformationOnTypeOfSubmittedReport><c:DateOfGeneralMeeting contextRef="c179">2021-11-30</c:DateOfGeneralMeeting><c:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="c179" xml:lang="en">David Dean Krenbrink</c:NameAndSurnameOfChairmanOfGeneralMeeting><c:NameOfReportingEntity contextRef="c179" xml:lang="en">Nature's BioCeuticals Denmark ApS</c:NameOfReportingEntity><c:AddressOfReportingEntityStreetName contextRef="c179" xml:lang="en">Hedebovej 47</c:AddressOfReportingEntityStreetName><c:AddressOfReportingEntityPostCodeIdentifier contextRef="c179" xml:lang="en">5474 Veflinge</c:AddressOfReportingEntityPostCodeIdentifier><d:TypeOfAuditorAssistance contextRef="c179" xml:lang="en">Andre erklæringer uden sikkerhed</d:TypeOfAuditorAssistance><c:IdentificationNumberCvrOfReportingEntity contextRef="c179" xml:lang="en">41912367</c:IdentificationNumberCvrOfReportingEntity><c:DateOfFoundationOfReportingEntity contextRef="c179">2020-12-04</c:DateOfFoundationOfReportingEntity><c:RegisteredOfficeOfReportingEntity contextRef="c179" xml:lang="en">Nordfyns</c:RegisteredOfficeOfReportingEntity><c:ReportingPeriodStartDate contextRef="c179">2020-12-04</c:ReportingPeriodStartDate><c:ReportingPeriodEndDate contextRef="c179">2021-06-30</c:ReportingPeriodEndDate><d:NameOfAuditFirm contextRef="c179" xml:lang="en">BDO Statsautoriseret revisionsaktieselskab</d:NameOfAuditFirm><c:AddressOfAuditorStreetName contextRef="c179" xml:lang="en">Fælledvej</c:AddressOfAuditorStreetName><c:AddressOfAuditorStreetBuildingIdentifier contextRef="c179" xml:lang="en">1</c:AddressOfAuditorStreetBuildingIdentifier><c:AddressOfAuditorPostCodeIdentifier contextRef="c179" xml:lang="en">5000</c:AddressOfAuditorPostCodeIdentifier><c:AddressOfAuditorDistrictName contextRef="c179" xml:lang="en">Odense C</c:AddressOfAuditorDistrictName><e:PlaceOfSignatureOfStatement contextRef="c179" xml:lang="en">Veflinge</e:PlaceOfSignatureOfStatement><e:DateOfApprovalOfAnnualReport contextRef="c179">2021-11-15</e:DateOfApprovalOfAnnualReport><d:NameAndSurnameOfMemberOfExecutiveBoard contextRef="c844" xml:lang="en">David Dean Krenbrink</d:NameAndSurnameOfMemberOfExecutiveBoard><f:SignatureOfAuditorsPlace contextRef="c179" xml:lang="en">Odense</f:SignatureOfAuditorsPlace><f:SignatureOfAuditorsDate contextRef="c179">2021-11-15</f:SignatureOfAuditorsDate><d:NameOfAuditFirm contextRef="c363" xml:lang="en">BDO Statsautoriseret revisionsaktieselskab</d:NameOfAuditFirm><d:IdentificationNumberCvrOfAuditFirm contextRef="c363" xml:lang="en">20222670</d:IdentificationNumberCvrOfAuditFirm><d:NameAndSurnameOfAuditor contextRef="c363" xml:lang="en">Morten Svensson</d:NameAndSurnameOfAuditor><d:TypeOfAuditorAssistance contextRef="c179" xml:lang="en">Andre erklæringer uden sikkerhed</d:TypeOfAuditorAssistance><d:DescriptionOfAuditor contextRef="c363" xml:lang="en">State Authorised Public Accountant</d:DescriptionOfAuditor><d:IdentificationNumberOfAuditor contextRef="c363" xml:lang="en">mne34505</d:IdentificationNumberOfAuditor><g:GrossProfitLoss contextRef="c179" unitRef="u1" decimals="0">-14627</g:GrossProfitLoss><g:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="c179" unitRef="u1" decimals="0">10000</g:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss><g:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="c179" unitRef="u1" decimals="0">-24627</g:ProfitLossFromOrdinaryActivitiesBeforeTax><g:TaxExpenseOnOrdinaryActivities contextRef="c179" unitRef="u1" decimals="0">-4611</g:TaxExpenseOnOrdinaryActivities><g:ProfitLoss contextRef="c179" unitRef="u1" decimals="0">-20016</g:ProfitLoss><g:ProfitLoss contextRef="c218" unitRef="u1" decimals="0">-20016</g:ProfitLoss><g:AcquiredIntangibleAssets contextRef="c177" unitRef="u1" decimals="0">190000</g:AcquiredIntangibleAssets><g:IntangibleAssets contextRef="c177" unitRef="u1" decimals="0">190000</g:IntangibleAssets><g:NoncurrentAssets contextRef="c177" unitRef="u1" decimals="0">190000</g:NoncurrentAssets><g:CurrentDeferredTaxAssets contextRef="c177" unitRef="u1" decimals="0">2200</g:CurrentDeferredTaxAssets><g:ShorttermTaxReceivablesFromGroupEnterprises contextRef="c177" unitRef="u1" decimals="0">2411</g:ShorttermTaxReceivablesFromGroupEnterprises><g:ShorttermReceivables contextRef="c177" unitRef="u1" decimals="0">4611</g:ShorttermReceivables><g:CashAndCashEquivalents contextRef="c177" unitRef="u1" decimals="0">35373</g:CashAndCashEquivalents><g:Assets contextRef="c177" unitRef="u1" decimals="0">229984</g:Assets><g:ContributedCapital contextRef="c177" unitRef="u1" decimals="0">40000</g:ContributedCapital><g:RetainedEarnings contextRef="c177" unitRef="u1" decimals="0">-20016</g:RetainedEarnings><g:Equity contextRef="c177" unitRef="u1" decimals="0">19984</g:Equity><g:ShorttermTradePayables contextRef="c177" unitRef="u1" decimals="0">10000</g:ShorttermTradePayables><g:ShorttermPayablesToGroupEnterprises contextRef="c177" unitRef="u1" decimals="0">200000</g:ShorttermPayablesToGroupEnterprises><g:ShorttermLiabilitiesOtherThanProvisions contextRef="c177" unitRef="u1" decimals="0">210000</g:ShorttermLiabilitiesOtherThanProvisions><g:LiabilitiesOtherThanProvisions contextRef="c177" unitRef="u1" decimals="0">210000</g:LiabilitiesOtherThanProvisions><g:LiabilitiesAndEquity contextRef="c177" unitRef="u1" decimals="0">229984</g:LiabilitiesAndEquity><g:Equity contextRef="c236" unitRef="u1" decimals="0">40000</g:Equity><g:Equity contextRef="c257" unitRef="u1" decimals="0">0</g:Equity><g:ProfitLoss contextRef="c256" unitRef="u1" decimals="0">-20016</g:ProfitLoss><g:Equity contextRef="c237" unitRef="u1" decimals="0">40000</g:Equity><g:Equity contextRef="c258" unitRef="u1" decimals="0">-20016</g:Equity><g:AverageNumberOfEmployees contextRef="c179" unitRef="u0" decimals="0">1</g:AverageNumberOfEmployees><g:CurrentTaxExpense contextRef="c179" unitRef="u1" decimals="0">-2411</g:CurrentTaxExpense><g:AdjustmentsForDeferredTax contextRef="c179" unitRef="u1" decimals="0">-2200</g:AdjustmentsForDeferredTax><g:TaxExpenseOnOrdinaryActivities contextRef="c179" unitRef="u1" decimals="0">-4611</g:TaxExpenseOnOrdinaryActivities><g:AdditionsToIntangibleAssets contextRef="c365" unitRef="u1" decimals="0">200000</g:AdditionsToIntangibleAssets><g:IntangibleAssetsGross contextRef="c368" unitRef="u1" decimals="0">200000</g:IntangibleAssetsGross><g:AmortisationOfIntangibleAssets contextRef="c365" unitRef="u1" decimals="0">10000</g:AmortisationOfIntangibleAssets><g:AccumulatedImpairmentLossesAndAmortisationOfIntangibleAssets contextRef="c368" unitRef="u1" decimals="0">10000</g:AccumulatedImpairmentLossesAndAmortisationOfIntangibleAssets><g:IntangibleAssets contextRef="c368" unitRef="u1" decimals="0">190000</g:IntangibleAssets><g:ClassOfReportingEntity contextRef="c179">Regnskabsklasse B</g:ClassOfReportingEntity><g:SelectedElementsFromReportingClassC contextRef="c179">true</g:SelectedElementsFromReportingClassC><g:AccountingPoliciesAreUnchangedFromPreviousPeriod contextRef="c179">true</g:AccountingPoliciesAreUnchangedFromPreviousPeriod><e:IdentificationOfApprovedAnnualReport contextRef="c179">Today the Executive Board have discussed and approved the Annual Report of Nature's BioCeuticals Denmark ApS for the financial year 4 December 2020  - 30 June 2021.






</e:IdentificationOfApprovedAnnualReport><e:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="c179">The Annual Report is presented in accordance with the Danish Financial Statements Act.






</e:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement><e:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="c179">In my opinion the Financial Statements give a true and fair view of the Company's assets, liabilities and financial position at 30 June 2021 and of the results of the Company's operations for the financial year 4 December 2020  - 30 June 2021.







</e:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults><e:ManagementsStatementAboutManagementsReview contextRef="c179">The Management Commentary includes in my opinion a fair presentation of the matters dealt with in the Commentary.








</e:ManagementsStatementAboutManagementsReview><e:ConfirmationThatFinancialStatementsAreExemptedFromAuditing contextRef="c179">The board of executives remain of the opinion that the conditions for opting out of audit have been fulfilled. 



</e:ConfirmationThatFinancialStatementsAreExemptedFromAuditing><e:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="c179">I recommend the Annual Report be approved at the Annual General Meeting.



</e:RecommendationForApprovalOfAnnualReportByGeneralMeeting><f:AddresseeOfAuditorsReportOnOtherReport contextRef="c179">To the Shareholders of Nature's BioCeuticals Denmark ApS




</f:AddresseeOfAuditorsReportOnOtherReport><f:DescriptionOfOtherEngagement contextRef="c179">We have compiled these Financial Statements of Nature's BioCeuticals Denmark ApS for the financial year 4 December 2020 - 30 June 2021 based on the Company's accounting records and other information provided by Management. 


These Financial Statements comprise income statement, balance sheet, statement of changes in equity, notes and accounting policies. 


We performed this compilation engagement in accordance with the International Standard, Compilation Engagements. 


We have applied our professional expertise to assist Management in the preparation and presentation of these Financial Statements in accordance with the Danish Financial Statements Act. We have complied with relevant statutory provisions of the Danish Audit Act, the International Ethics Standards Board for Accountants’ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark. 


These Financial Statements and the accuracy and completeness of the information used to compile these Financial Statements are Management’s responsibility. 


Since an engagement to compile financial information is not an assurance engagement, we are not required to verify the accuracy or completeness of the information provided by Management to us to compile these Financial Statements. Accordingly, we do not express an audit opinion or a review conclusion on whether these Financial Statements are prepared in accordance with the Danish Financial Statements Act. 

</f:DescriptionOfOtherEngagement><h:DescriptionOfPrimaryActivitiesOfEntity contextRef="c179">Principal activities




The principal activities comprise trading and production of medical cannabis and associated activities. 


</h:DescriptionOfPrimaryActivitiesOfEntity><h:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod contextRef="c179">Significant events after the end of the financial year




No events have occurred after the end of the financial year of material importance for the Company's financial position. 


</h:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod><g:DisclosureOfEquity contextRef="c179">Share capital
Retained earnings
Total




Equity at 4 December 2020 
40.000
0
40.000






Proposed profit allocation  

-20.016
-20.016






Equity at 30 June 2021 
40.000
-20.016
19.984














</g:DisclosureOfEquity><g:DisclosureOfEmployeeBenefitsExpense contextRef="c179">Staff costs

1

Average number of employees
1











</g:DisclosureOfEmployeeBenefitsExpense><g:DisclosureOfTaxExpenseOnOrdinaryActivities contextRef="c179">Tax on profit/loss for the year

2

Calculated tax on taxable income of the year 
-2.411


Adjustment of deferred tax 
-2.200







-4.611



</g:DisclosureOfTaxExpenseOnOrdinaryActivities><g:DisclosureOfIntangibleAssets contextRef="c179">Intangible assets

3



Intangible fixed assets acquired


Additions 
200.000
Cost at 30 June 2021 
200.000


Amortisation for the year 
10.000
Amortisation at 30 June 2021 
10.000


Carrying amount at 30 June 2021 
190.000



</g:DisclosureOfIntangibleAssets><g:DisclosureOfContingentLiabilities contextRef="c179">Contingent liabilities

None
</g:DisclosureOfContingentLiabilities><g:InformationOnReportingClassOfEntity contextRef="c179">The Annual Report of Nature's BioCeuticals Denmark ApS for 2020/21 has been presented in accordance with the provisions of the Danish Financial Statements Act for enterprises in reporting class B and certain provisions applying to reporting class C. 
Regnskabsklasse B1
true
true

The Annual Report is prepared with the following accounting principles. 


</g:InformationOnReportingClassOfEntity><g:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="c179">Other external expenses



Other external expenses include other production, sales, delivery and administrative costs, including costs of energy, marketing, premises, loss on bad debts,  lease expenses, etc 


</g:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses><g:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="c179">Tax





The tax for the year, which consists of the current tax for the year and changes in deferred tax, is recognised in the Income Statement by the share that may be attributed to the profit for the year, and is recognised directly in equity by the share that may be attributed to entries directly to equity. 


</g:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses><g:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfIntangibleAssets contextRef="c179">Intangible fixed assets





Patents and licences are measured at the lower of cost less accumulated amortisation and the recoverable amount. Patents are amortised over the remaining patent period and licences are amortised over the period of the agreement, however, no more than 8 years. 



Profit or loss from sale of intangible fixed assets is calculated at the difference between the sales price and the carrying amount at the time of the sale. Profit and loss are recognised in the Income Statement under other operating income or other operating expenses.  



</g:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfIntangibleAssets><g:DescriptionOfMethodsOfAmortisationOfNoncurrentAssets contextRef="c179">Impairment of fixed assets





The carrying amount of intangible fixed assets, are assessed annually for indications of impairment other than that reflected by amortisation and depreciation. 



In the event of impairment indications, an impairment test is made for each asset or group of assets, respectively. If the recoverable amount is lower than the carrying amount, the asset is written down to the recoverable amount. 



The recoverable amount is calculated at the higher of the capital value and the sales value less expected costs of a sale. The capital value is determined as the Company's share in the current value of the net cash flows which the subsidiary is expected to generate through its activities and from sale of assets after the end of their useful lives. A discount rate is used which reflects the risk-free market rate and the owners' minimum return on interest requirements for similar assets. The growth rate in the terminal period is determined in accordance with the standards within the industry. 



</g:DescriptionOfMethodsOfAmortisationOfNoncurrentAssets><g:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax contextRef="c179">Tax payable and deferred tax




Current tax liabilities and receivable current tax are recognised in the Balance Sheet as the calculated tax on the taxable income for the year, adjusted for tax on the taxable income for previous years and taxes paid on account. 



Deferred tax is measured on the temporary differences between the carrying amount and the tax value of assets and liabilities. 



Deferred tax assets, including the tax value of tax loss carryforwards, are measured at the amount at which the asset is expected to be used within a reasonable number of years, either by setoff against tax on future earnings or by setoff against deferred tax liabilities within the same legal tax entity. 



Deferred tax is measured on the basis of the tax rules and tax rates that under the legislation in force on the Balance Sheet date will be applicable when the deferred tax is expected to crystallise as current tax. Any changes in the deferred tax resulting from changes in tax rates, are recognised in the income statement, except from items recognised directly in equity. 


</g:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax><g:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="c179">Liabilities





Financial liabilities are recognised at the time of borrowing by the amount of proceeds received less transaction costs. In subsequent periods, the financial liabilities are measured at amortised cost equal to the capitalised value when using the effective interest, the difference between the proceeds and the nominal value being recognised in the Income Statement over the loan period. 



The amortised cost of current liabilities corresponds usually to the nominal value. 



</g:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions><!--Slutdato for aktuelle periode--><context id="c177"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2021-06-30</instant></period></context><!--Aktuelle periode--><context id="c179"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2020-12-04</startDate><endDate>2021-06-30</endDate></period></context><!--Overfoert resultat--><context id="c218"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2020-12-04</startDate><endDate>2021-06-30</endDate></period><scenario><xbrldi:explicitMember dimension="g:ResultDistributionDimension">g:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--EG kapital primo--><context id="c236"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2020-12-04</instant></period><scenario><xbrldi:explicitMember dimension="g:ClassesOfEquityDimension">g:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--EG kapital ultimo--><context id="c237"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2021-06-30</instant></period><scenario><xbrldi:explicitMember dimension="g:ClassesOfEquityDimension">g:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--EG resultat bev--><context id="c256"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2020-12-04</startDate><endDate>2021-06-30</endDate></period><scenario><xbrldi:explicitMember dimension="g:ClassesOfEquityDimension">g:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--EG resultat primo--><context id="c257"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2020-12-04</instant></period><scenario><xbrldi:explicitMember dimension="g:ClassesOfEquityDimension">g:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--EG resultat ultimo--><context id="c258"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2021-06-30</instant></period><scenario><xbrldi:explicitMember dimension="g:ClassesOfEquityDimension">g:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Revisor1 Ny--><context id="c363"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2020-12-04</startDate><endDate>2021-06-30</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfAuditorDimension"><d:auditorIdentifier>1</d:auditorIdentifier></xbrldi:typedMember></scenario></context><!--Immat erhv bev--><context id="c365"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2020-12-04</startDate><endDate>2021-06-30</endDate></period><scenario><xbrldi:explicitMember dimension="g:ClassesOfIntangibleAssetsDimension">g:AcquiredIntangibleAssetsMember</xbrldi:explicitMember></scenario></context><!--Immat erhv ultimo--><context id="c368"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2021-06-30</instant></period><scenario><xbrldi:explicitMember dimension="g:ClassesOfIntangibleAssetsDimension">g:AcquiredIntangibleAssetsMember</xbrldi:explicitMember></scenario></context><!--Ledelse1--><context id="c844"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2020-12-04</startDate><endDate>2021-06-30</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfMemberOfExecutiveBoardDimension"><d:memberOfBoardIdentifier>1</d:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--Nogletal 0 dec--><unit id="u0"><measure>xbrli:pure</measure></unit><!--DKK--><unit id="u1"><measure>iso4217:DKK</measure></unit></xbrl>